Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
Journal
Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
24
05
2020
revised:
19
08
2020
accepted:
05
09
2020
pubmed:
12
10
2020
medline:
14
10
2021
entrez:
11
10
2020
Statut:
ppublish
Résumé
Therapeutic drug monitoring (TDM) plays a vital role in implementing precision medicine in inflammatory bowel disease (IBD), and may contribute to increased effectiveness, lower rates of drug toxicity and cost savings. While expert panels advocate the use of reactive TDM for anti-tumor necrosis factor (anti-TNF) agents, TDM is not yet widely recommended for non-anti TNF biologicals. We provide an overview of the observational evidence of the value of TDM in case of vedolizumab and ustekinumab. We also shed light on obstacles that need to be addressed before establishing wide acceptance of TDM in the field of IBD. In this respect, new analytical techniques and modelling approaches are being developed to further optimize efficacy of TDM and to facilitate general acceptance of this tool in personalizing IBD management.
Identifiants
pubmed: 33039940
pii: S1471-4892(20)30082-5
doi: 10.1016/j.coph.2020.09.002
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Gastrointestinal Agents
0
vedolizumab
9RV78Q2002
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
17-30Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.